Tarsus Pharmaceuticals, Inc. TARS
Set alert
At close
Pre-market · Nov 2, 8:30 AM ET
- YTD
- -8.59%
- 1 year
- +8.78%
- Open
- 74.99
- Prev close
- 74.85
- Mkt cap
- 3.50B
- Vol
- 595.21K
- Avg vol
- 834.77K
- EPS
- -1.08
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 74.30
- High
- 76.27
- Forward P/E
- -150.06
- Beta
- 0.45
- Short ratio
- 6.62
- Inst. own
- 99.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 75.09
- 200-d avg
- 67.78
- 1y target
- 99.56
5D chart
Signals (111)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 10:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:15 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:05 AM | 3 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:45 PM | 3 days ago |
| RSI: Overbought | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:20 AM | 4 days ago |
| RSI: Overbought | Oct 29, 10:00 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:00 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:50 AM | 5 days ago |
| RSI: Overbought | Oct 27, 11:25 AM | 5 days ago |
| RSI: Overbought | Oct 27, 11:05 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:35 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 6 days ago |
| MACD: Sell Signal | Oct 27, 9:35 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 6 days ago |
| RSI: Overbought | Oct 26, 11:00 AM | 6 days ago |
| RSI: Overbought | Oct 26, 10:50 AM | 6 days ago |
News
1 day ago seekingalpha.com
My 'Eye' Is On Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is well-positioned with Xdemvy's rapid commercial ramp and robust $2B peak sales potential. Recent acquisitions of IRX-101 and ALK-101 diversify the pipeline, adding both…
3 days ago globenewswire.com
Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
IRVINE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 3,…
5 days ago globenewswire.com
Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
IRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), effective Nov. 1, 2026.…
5 days ago zacks.com
Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline
Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
1 month ago benzinga.com
Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and announces $116 price target.
-
1 month ago benzinga.com
Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target
Barclays analyst Glen Santangelo reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and announces $110 price target.
-
1 month ago benzinga.com
Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105
Jefferies analyst Anthony Petrone maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $88 to $105.
-
2 months ago benzinga.com
Alkeus Pharmaceuticals Receives Orphan Drug Designation From Japan's Ministry Of Health, Labour, And Welfare For Oral Gildeuretinol To Treat Stargardt Disease
Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that the Ministry of Health, Labour and…
-
2 months ago benzinga.com
Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100
Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $97 to $100.
-
2 months ago benzinga.com
Tarsus Pharmaceuticals Q2 EPS $(0.43) Misses $(0.20) Estimate, Sales $173.912M Beat $169.677M Estimate
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.20) by 115 percent. This is a 10.42 percent increase over losses…
-
2 months ago benzinga.com
Tarsus Pharmaceuticals To Acquire Alkeus Pharmaceuticals, A Closely Held Biotech Firm Developing Gildeuretinol, An Investigational Once-Daily Oral Therapy For Stargardt Disease; Terms Not Disclosed
Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of…
-
3 months ago benzinga.com
Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98
Mizuho analyst Graig Suvannavejh maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and lowers the price target from $100 to $98.
-
3 months ago benzinga.com
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $89
Guggenheim analyst Brad Canino maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and lowers the price target from $90 to $89.
3 months ago benzinga.com
Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug
Tarsus acquires iRenix to add IRX-101, with Phase 3 planned for 2027, as William Blair calls the deal a disciplined pipeline expansion.
-
3 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $88 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and maintains $88 price target.
-
3 months ago benzinga.com
Tarsus Acquires iRenix Medical And Late-Stage Asset IRX-101 For ~$75M
IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of carePositive Phase 2b/3 data and an FDA-aligned Phase 3 program provide…
4 months ago benzinga.com
Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) shares are falling Wednesday. Short-seller Culper Research published a report Wednesday alleging the company's sole commercial product relies on an illegal…
-
5 months ago benzinga.com
Tarsus Pharmaceuticals Collaborates With John Cena Over Eyelid Disease Demodex Blepharitis
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but often overlooked eyelid disease caused by…
-
6 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $88 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and maintains $88 price target.
-
7 months ago benzinga.com
Tarsus Pharma Says First Participant Dosed In Phase 2 Clinical Trial Evaluating TP-05, Investigational Oral Therapy To Prevent Lyme Disease By Killing Lyme-Infected Ticks Before Disease Transmission Occurs
– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission –IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals,…
-
7 months ago benzinga.com
Tarsus Pharmaceuticals Announces $15M Milestone Payment Achieved After Regulatory Approval Of TP-03 By China's National Medical Products Administration
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory approval of TP-03 (lotilaner ophthalmic solution)…
-
8 months ago benzinga.com
Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $105
Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $95 to $105.
-
8 months ago benzinga.com
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $90
Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $87 to $90.
8 months ago benzinga.com
Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday
Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday
-
8 months ago benzinga.com
Tarsus Pharmaceuticals Q4 EPS $(0.20) Misses $(0.11) Estimate, Sales $151.668M Beat $144.565M Estimate
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.11) by 81.82 percent. This is a 66.67 percent increase over…
8 months ago benzinga.com
Insights into Tarsus Pharmaceuticals Q4 Earnings
Insights into Tarsus Pharmaceuticals Q4 Earnings
-
8 months ago benzinga.com
Earnings Scheduled For February 23, 2026
Earnings Scheduled For February 23, 2026
8 months ago benzinga.com
Earnings Preview: Tarsus Pharmaceuticals
Earnings Preview: Tarsus Pharmaceuticals
-
10 months ago benzinga.com
Barclays Initiates Coverage On Tarsus Pharmaceuticals with Overweight Rating, Announces Price Target of $100
Barclays analyst Glen Santangelo initiates coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight rating and announces Price Target of $100.
-
11 months ago benzinga.com
Mizuho Initiates Coverage On Tarsus Pharmaceuticals with Outperform Rating, Announces Price Target of $100
Mizuho analyst Graig Suvannavejh initiates coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform rating and announces Price Target of $100.
12 months ago benzinga.com
Earnings Scheduled For November 4, 2025
Earnings Scheduled For November 4, 2025
-
1 year ago benzinga.com
Earnings Scheduled For February 25, 2025
Earnings Scheduled For February 25, 2025
-
1 year ago benzinga.com
Earnings Scheduled For November 13, 2024
Earnings Scheduled For November 13, 2024
-
2 years ago benzinga.com
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
-
2 years ago benzinga.com
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
-
2 years ago benzinga.com
SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday
U.S. stocks traded mixed, with the Dow Jones trading slightly lower on Monday. Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) rose sharply during Monday’s session after the company reported…
-
2 years ago benzinga.com
Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Wynn Resorts, Limited (NASDAQ: WYNN) fell sharply on Friday after the company reported third-quarter financial results.
-
2 years ago benzinga.com
Big Stocks Moving Higher On Friday: Synaptics Reports Q1 Beat; Joins Lyft, Hologic, Blink Charging
U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Friday. Shares of Synaptics Incorporated (NASDAQ: SYNA) rose sharply on Friday after the company reported…
-
2 years ago benzinga.com
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
3 years ago benzinga.com
Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Aurora Acquisition Corp. (NASDAQ: AURC) shares jumped 192% to $30.54.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 1043 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 211 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
Friday's session saw 466 companies set new 52-week highs.